{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:10:39Z","timestamp":1768990239315,"version":"3.49.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.yrtph.2024.105745","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T15:48:04Z","timestamp":1732290484000},"page":"105745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Considerations and derivations of permitted daily exposure limits for impurities from intravitreal pharmaceutical products"],"prefix":"10.1016","volume":"155","author":[{"given":"Yi","family":"Yu Rice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suren B.","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan E.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Garry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yrtph.2024.105745_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"issue":"9","key":"10.1016\/j.yrtph.2024.105745_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11095-018-2450-1","article-title":"Safety assessment of formulation vehicles following intravitreal administration in rabbits","volume":"35","author":"Aguirre","year":"2018","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.yrtph.2024.105745_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/antiox9010007","article-title":"Vitreous antioxidants, degeneration, and vitreo-retinopathy: exploring the links","volume":"20","author":"Ankamah","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.yrtph.2024.105745_bib4","series-title":"Standard Guide for Derivation of Health-Based Exposure Limits (HBELs)","first-page":"E3219","year":"2020"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.9.1.2","article-title":"In vivo measurement of the human vitreous chamber volume using computed tomography imaging of 100 eyes","volume":"29","author":"Azhdam","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.yrtph.2024.105745_bib6","series-title":"Chapter 2. Water: the Solvent for Biochemical Reactions in Biochemistry","first-page":"49","author":"Campbell","year":"2008"},{"key":"10.1016\/j.yrtph.2024.105745_bib7","series-title":"Right Eye Illustration","author":"Carlson","year":"2024"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0041-008X(75)90174-X","article-title":"Experimental methanol toxicity in the primate: analysis of metabolic acidosis","volume":"34","author":"Clay","year":"1975","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105745_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/IAE.0b013e31806dafb7","article-title":"Buffering capacity of bovine vitreous","volume":"28","author":"Conway","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.yrtph.2024.105745_bib10","series-title":"Pharmacology of Ocular Therapeutics","article-title":"Drug transport across blood-ocular barriers and pharmacokinetics","author":"Cunha-Vaz","year":"2016"},{"key":"10.1016\/j.yrtph.2024.105745_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.yrtph.2017.03.013","article-title":"Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics","volume":"86","author":"de Zafra","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105745_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data","volume":"137","author":"Del Amo","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.yrtph.2024.105745_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"issue":"5","key":"10.1016\/j.yrtph.2024.105745_bib14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/s11095-008-9728-7","article-title":"Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR)","volume":"26","author":"Durairaj","year":"2009","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1076\/ceyr.22.1.74.6974","article-title":"Quantitative analysis of intravitreal injections in the rat","volume":"22","author":"Dureau","year":"2001","journal-title":"Curr. Eye Res."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105745_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/1389200043335342","article-title":"Role of metabolism in ocular drug delivery","volume":"5","author":"Duvvuri","year":"2004","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.yrtph.2024.105745_bib17","series-title":"Registration Dossier for Formic Acid. CAS Number 64-18-6","year":"2022"},{"key":"10.1016\/j.yrtph.2024.105745_bib18","series-title":"Registration Dossier for Acetic Acid. CAS Number 64-19-7","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105745_bib19","series-title":"Registration Dossier for Caprolactam. CAS Number 105-60-2","year":"2023"},{"issue":"3","key":"10.1016\/j.yrtph.2024.105745_bib20","first-page":"321","article-title":"Development and characterization of a rodent model of methanol-induced retinal and optic nerve toxicity","volume":"21","author":"Eells","year":"2000","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.yrtph.2024.105745_bib21","first-page":"1","volume":"414","year":"2006","journal-title":"EFSA J."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib22","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.2903\/j.efsa.2013.3060","article-title":"Conclusion on the peer review of the pesticide risk assessment of the active substance acetic acid","volume":"11","year":"2013","journal-title":"EFSA J."},{"issue":"6","key":"10.1016\/j.yrtph.2024.105745_bib23","first-page":"5293","article-title":"Refined exposure assessment of polyethylene glycol(E 1521) from its use as a food additive","volume":"16","year":"2018","journal-title":"EFSA J."},{"key":"10.1016\/j.yrtph.2024.105745_bib24","series-title":"Application of Alternative Methods in the Regulatory Assessment of Chemical Safety Related to Human Eye Irritation and Severe Eye Irritation","author":"Eskes","year":"2010"},{"key":"10.1016\/j.yrtph.2024.105745_bib25","article-title":"Regulation (EC) No 1333\/2008 of the European parliament and of the council of 16 december 2008 on food additives","year":"2008","journal-title":"Off. J. Eur. Union"},{"key":"10.1016\/j.yrtph.2024.105745_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.yrtph.2019.01.029","article-title":"Improving risk assessment approaches for chemicals with both endogenous and exogenous exposures","volume":"103","author":"Farland","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105745_bib27","series-title":"CFR - Code of Federal Regulations Title 21. Sec. 177.1500 Nylon Resins","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105745_bib28","series-title":"CFR - Code of Federal Regulations Title 21. Sec. 184.1005 Acetic Acid","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105745_bib29","series-title":"CFR - Code of Federal Regulations Title 21. Sec. 186.1316 Formic Acid","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105745_bib30","series-title":"Inactive Ingredient Search for Approved Drug Products","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105745_bib31","series-title":"Pharmaceutical Quality\/CMC . Quality Considerations for Topical Ophthalmic Drug Products Guidance for Industry. Revision 1 U.S. Department of Health nd Human Services. Food and Drug Administration","year":"2023"},{"issue":"3","key":"10.1016\/j.yrtph.2024.105745_bib32","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acs.molpharmaceut.0c01154","article-title":"Carboxylesterase activities and protein expression in rabbit and pig ocular tissues","volume":"18","author":"Hammid","year":"2021","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105745_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1600-0773.2001.890202.x","article-title":"Ocular changes after intravitreal injection of methanol, formaldehyde, or formate in rabbits","volume":"89","author":"Hayasaka","year":"2001","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.yrtph.2024.105745_bib34","series-title":"Contemporary Practice in Clinical Chemistry","first-page":"37","article-title":"Chapter 3 - reference intervals: theory and practice","author":"Higgins","year":"2020"},{"issue":"3","key":"10.1016\/j.yrtph.2024.105745_bib35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5731\/pdajpst.2022.012744","article-title":"Principles for management of extractables and leachables in ophthalmic drug products","volume":"76","author":"Houston","year":"2022","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.yrtph.2024.105745_bib36","series-title":"Q3D(R2): Guideline for Elemental Impurities","year":"2022"},{"key":"10.1016\/j.yrtph.2024.105745_bib37","series-title":"M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk (Step 4) (3 April 2023)","year":"2023"},{"key":"10.1016\/j.yrtph.2024.105745_bib38","series-title":"Q3C(R9): Impurities: Guideline for Residual Solvents","year":"2024"},{"key":"10.1016\/j.yrtph.2024.105745_bib39","series-title":"Chemical-Specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose\/Concentration-Response Assessment","year":"2005"},{"key":"10.1016\/j.yrtph.2024.105745_bib40","volume":"vol. 648","year":"1980"},{"issue":"4414","key":"10.1016\/j.yrtph.2024.105745_bib41","article-title":"Vitreous volume of the mouse measured by quantitative high-resolution MRI. Investigative ophthalmology & visual science","volume":"51","author":"Kaplan","year":"2010","journal-title":"ARVO Annual Meeting Abstract"},{"issue":"12","key":"10.1016\/j.yrtph.2024.105745_bib42","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1007\/s11095-012-0822-5","article-title":"Prediction of the vitreal half-life of small molecular drug-like compounds","volume":"29","author":"Kidron","year":"2012","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.yrtph.2024.105745_bib43","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.survophthal.2010.09.001","article-title":"Vitreous substitutes: a comprehensive review","volume":"56","author":"Kleinberg","year":"2011","journal-title":"Surv. Ophthalmol."},{"issue":"7","key":"10.1016\/j.yrtph.2024.105745_bib44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/ceo.12732","article-title":"Biochemical analysis of the living human vitreous","volume":"44","author":"Kokavec","year":"2016","journal-title":"Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105745_bib45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/01480545.2010.500292","article-title":"Systemic toxicity and toxicokinetics of a high dose of polyethylene glycol 400 in dogs following intravenous injection","volume":"34","author":"Li","year":"2011","journal-title":"Drug Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105745_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1113\/jphysiol.1970.sp009133","article-title":"Changes in the blood volume of the rabbit with age","volume":"208","author":"Little","year":"1970","journal-title":"J. Physiol."},{"key":"10.1016\/j.yrtph.2024.105745_bib47","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yrtph.2018.10.007","article-title":"Use of the permitted daily exposure (PDE) concept for contaminants of intravitreal (IVT) drugs in multipurpose manufacturing facilities","volume":"101","author":"Lovsin Barle","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"18","key":"10.1016\/j.yrtph.2024.105745_bib48","doi-asserted-by":"crossref","first-page":"16229","DOI":"10.1074\/jbc.M110.204701","article-title":"Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization","volume":"286","author":"Lyzogubov","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.yrtph.2024.105745_bib49","series-title":"Polyethylene Glycol [MAK Value Documentation, 1998]","article-title":"The MAK\u2010collection for occupational health and safety documentations and methods","year":"1998"},{"key":"10.1016\/j.yrtph.2024.105745_bib50","series-title":"The MAK\u2010Collection for Occupational Health and Safety Documentations and Methods","year":"2003"},{"key":"10.1016\/j.yrtph.2024.105745_bib51","series-title":"The MAK\u2010Collection for Occupational Health and Safety Documentations and Methods","year":"2010"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0041-008X(78)90040-6","article-title":"Methanol poisoning: ocular toxicity produced by formate","volume":"45","author":"Martin-Amat","year":"1978","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.yrtph.2024.105745_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/0006-2944(75)90171-4","article-title":"Methanol poisoning. I. The role of formic acid in the development of metabolic acidosis in the monkey and the reversal by 4-methylpyrazole","volume":"13","author":"McMartin","year":"1975","journal-title":"Biochem. Med."},{"key":"10.1016\/j.yrtph.2024.105745_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107789","article-title":"pH balance and lactic acid increase in the vitreous body of diabetes mellitus patients","volume":"188","author":"Mieno","year":"2019","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105745_bib55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02713683.2022.2119254","article-title":"Vitreous humor: composition, characteristics and implication on intravitreal drug delivery","volume":"48","author":"Mishra","year":"2023","journal-title":"Curr. Eye Res."},{"issue":"12","key":"10.1016\/j.yrtph.2024.105745_bib56","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1007\/s11095-012-0721-9","article-title":"Simulating intravitreal injections in anatomically accurate models for rabbit, monkey, and human eyes","volume":"29","author":"Missel","year":"2012","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/ijms21010211","article-title":"Tight junctions of the outer blood retina barrier","volume":"27","author":"Naylor","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yrtph.2024.105745_bib59","series-title":"SIDS Initial Assessment Profile","first-page":"105","year":"2001"},{"key":"10.1016\/j.yrtph.2024.105745_bib60","series-title":"The Office of Environmental Health Hazard Assessment. Reference Exposure Levels (RELs) for Caprolactam","year":"2013"},{"issue":"3","key":"10.1016\/j.yrtph.2024.105745_bib61","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-021-01949-4","article-title":"Container closure and delivery considerations for intravitreal drug administration","volume":"22","author":"Parenky","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.yrtph.2024.105745_bib62","doi-asserted-by":"crossref","first-page":"430","DOI":"10.5731\/pdajpst.2013.00936","article-title":"The product quality research institute (PQRI) leachables and extractables working group initiatives for parenteral and ophthalmic drug product (PODP)","volume":"67","author":"Paskiet","year":"2013","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.yrtph.2024.105745_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.molmet.2019.05.012","article-title":"Formate metabolism in health and disease","volume":"33","author":"Pietzke","year":"2020","journal-title":"Mol. Metabol."},{"issue":"15","key":"10.1016\/j.yrtph.2024.105745_bib64","article-title":"Role of the vitreous in retinal pathology: a narrative review","volume":"23","author":"Popescu","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.yrtph.2024.105745_bib65","series-title":"Caprolactam","year":"2024"},{"key":"10.1016\/j.yrtph.2024.105745_bib66","series-title":"Formic Acid","year":"2024"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib67","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1080\/10717544.2022.2069301","article-title":"The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery","volume":"29","author":"Ranade","year":"2022","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105745_bib68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/toxsci\/44.2.197","article-title":"Subchronic inhalation toxicity study of caprolactam (with a 4-week recovery) in the rat via whole-body exposures","volume":"44","author":"Reinhold","year":"1998","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2024.105745_bib69","series-title":"Clinical Anatomy and Physiology of the Visual System","first-page":"109","article-title":"Aqueous and vitreous humors","author":"Remington","year":"2012"},{"key":"10.1016\/j.yrtph.2024.105745_bib70","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1006\/rtph.1999.1329","article-title":"Duration of intake above the ADI\/TDI in relation to toxicodynamics and toxicokinetics","volume":"30","author":"Renwick","year":"1999","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2024.105745_bib71","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1006\/rtph.1999.1330","article-title":"Incidence and severity in relation to magnitude of intake above the ADI or TDI: use of critical effect data","volume":"30","author":"Renwick","year":"1999","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"7","key":"10.1016\/j.yrtph.2024.105745_bib72","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1021\/acs.molpharmaceut.1c00236","article-title":"Mechanistic model for the prediction of small-molecule vitreal clearance combining diffusion-limited and permeability-limited clearance","volume":"18","author":"Rimpel\u00e4","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.yrtph.2024.105745_bib73","series-title":"Handbook of Pharmaceutical Excipients","author":"Rowe","year":"2009"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11095-016-2037-7","article-title":"Estimation of intra-vitreal half-lifes in the rabbit eye with semi-mechanistic equations","volume":"34","author":"Schmitt","year":"2017","journal-title":"Pharm. Res."},{"issue":"14","key":"10.1016\/j.yrtph.2024.105745_bib75","first-page":"463","article-title":"Vitreous humor buffering capacity of rabbit, bovine, and porcine. ARVO Annual Meeting Abstract","volume":"53","author":"Shawer","year":"2012","journal-title":"Invest Opthalm Vis Sci"},{"issue":"3","key":"10.1016\/j.yrtph.2024.105745_bib76","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10837450.2017.1365370","article-title":"Profiling extractable and leachable inorganic impurities in ophthalmic drug containers by ICP-MS","volume":"23","author":"Solomon","year":"2018","journal-title":"Pharmaceut. Dev. Technol."},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib77","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.taap.2010.05.009","article-title":"Species differences in methanol and formic acid pharmacokinetics in mice, rabbits and primates","volume":"247","author":"Sweeting","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"9","key":"10.1016\/j.yrtph.2024.105745_bib78","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1002\/jps.22610","article-title":"Comparison of drug permeabilities across the blood\u2013retinal barrier, blood\u2013aqueous humor barrier, and blood\u2013brain barrier","volume":"100","author":"Toda","year":"2011","journal-title":"J. Pharmaceut. Sci."},{"issue":"2","key":"10.1016\/j.yrtph.2024.105745_bib79","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00006982-200404000-00023","article-title":"Retinal toxicity in methanol poisoning","volume":"24","author":"Treichel","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.yrtph.2024.105745_bib80","series-title":"Health and Environmental Effects Document for Formic Acid. Final Draft","year":"1990"},{"key":"10.1016\/j.yrtph.2024.105745_bib81","series-title":"Integrated Risk Information System (IRIS)","year":"2002"},{"key":"10.1016\/j.yrtph.2024.105745_bib82","series-title":"Provisional Peer-Reviewed Toxicity Values for Formic Acid (CASRN 64-18-6)","year":"2010"},{"issue":"3","key":"10.1016\/j.yrtph.2024.105745_bib83","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics12030269","article-title":"Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations","volume":"12","author":"Varela-Fern\u00e1ndez","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.yrtph.2024.105745_bib84","series-title":"Polyethylene Glycols","year":"1979"},{"issue":"1","key":"10.1016\/j.yrtph.2024.105745_bib85","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0939-6411(97)00064-7","article-title":"Ocular pharmacokinetics\/pharmacodynamics","volume":"44","author":"Worakul","year":"1997","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230024001867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T01:40:31Z","timestamp":1733967631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230024001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":84,"alternative-id":["S0273230024001867"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105745","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations and derivations of permitted daily exposure limits for impurities from intravitreal pharmaceutical products","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2024.105745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105745"}}